)
Visual
test
SCHOTT Pharma
SCHOTT Pharma (1SXP) investor relations material
SCHOTT Pharma Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary11 Dec, 2025
Executive summary
Achieved full-year revenue and profitability targets for FY 2025, with high-value solutions (HVS) reaching 57% of revenues and continued global expansion and innovation.
Significant progress in expanding production capacities and launching new products, supporting innovation leadership.
Leadership transition: Christian Meisel (or Mias) appointed CEO from May 2026, Reinhard Mayer as CFO from August 2025.
Financial highlights
FY 2025 revenues reached EUR 986 million, up 3% year-over-year (5.8% at constant currencies), with EBITDA margin at 28.4%.
EBIT grew by 4.3% to EUR 201 million; EPS was EUR 0.97, slightly down from EUR 0.99.
Dividend proposal increased to EUR 0.18 per share, marking the third consecutive rise since IPO.
Free cash flow for the year was EUR 37 million, impacted by higher working capital and tax payments.
Capital expenditure stable at EUR 145 million, focused on HVS capacity and innovation.
Outlook and guidance
FY 2026 organic revenue growth expected at 2%-5% at constant currencies, with EBITDA margin around 27% due to product mix and ramp-up costs.
Growth in 2026 to be driven by Drug Containment Solutions (DCS), while Drug Delivery Solutions (DDS) faces lower demand.
CapEx planned at EUR 140-160 million, focused on HVS capacity and innovation.
Midterm (2027-2029) revenue CAGR revised to 6%-8%, EBITDA margin to approach 30%.
What drives key customer's glass syringe demand drop?
Midterm guidance: What changed in market dynamics?
Future CapEx trajectory and U.S. expansion plans
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 7 FebEVK
FY 2025 guidance met with strong cash flow; new dividend policy and stable 2026 outlook set. - 7 FebSBIN
Q3 FY26 net profit hit INR 21,028 crore, driven by strong income and strategic divestments. - 7 FebGICRE
Net profit for the nine months surged to ₹6,62,217 lakhs, with a robust solvency ratio of 3.87. - 7 Feb517271
Strong revenue and profit growth, interim dividend, and major investments approved. - 7 Feb514167
Quarterly and nine-month results reflect solid revenue, profit, and compliance with new labour codes. - 7 FebMGL
Strong revenue growth offset by lower margins and profit; interim dividend declared. - 7 FebPGIL
Strong revenue and margin growth, with India set for further expansion and upgraded ratings. - 7 Feb504614
Strong revenue and profit growth in Q3 FY26, led by power and steel segments. - 7 FebCHEMPLASTS
Net losses widened and revenue fell year-over-year amid regulatory and market headwinds. - 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist.
Next SCHOTT Pharma earnings date
Q1 202611 Feb, 2026
SCHOTT Pharma
Next SCHOTT Pharma earnings date
Q1 202611 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
SCHOTT Pharma AG & Co. KGaA specializes in developing, producing, and selling advanced drug containment and delivery solutions for the injectable drugs market. Catering to the pharmaceutical and biotechnology industries globally, the company offers a comprehensive portfolio that includes polymer and glass syringes, ampoules, vials, and cartridges. Notable products in its range include the syriQ series of glass and polymer syringes designed for various applications such as vaccines, biologics, aesthetic treatments, infusion therapy, and deep-cold applications, as well as the cartriQ and adaptiQ lines for cartridges and vials, respectively. It is headquartered in Mainz, Germany, and its shares are listed on the Frankfurt Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage